MedTrace Logo

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

NCT00761696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2012-06-21

No results posted yet for this study

Summary

The primary objectives of the study are:

* To determine the safety and the maximum tolerated dose (MTD) of IPI-926
* To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s)
* To recommend a dose and schedule of IPI-926 for subsequent studies

Conditions

  • Neoplasms

Interventions

DRUG

IPI-926

Oral daily dosing

Sponsors & Collaborators

  • Infinity Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Ross, MD · Infinity Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761696 on ClinicalTrials.gov